Nephrology Unit- CHU Liège- Ulg- Belgium

Similar documents
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

Cardiovascular Diseases in CKD

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

surtout qui n est PAS à risque?

Protecting the heart and kidney: implications from the SHARP trial

Case Study: Chris Arden. Peripheral Arterial Disease

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Which CVS risk reduction strategy fits better to carotid US findings?

HTA ET DIALYSE DR ALAIN GUERIN

Echocardiography analysis in renal transplant recipients

NEW GUIDELINES FOR CHOLESTEROL

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Cardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

CKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology

CLINICAL OUTCOME Vs SURROGATE MARKER

Prevention of MACROvascular Complications of Diabetes

LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

The TNT Trial Is It Time to Shift Our Goals in Clinical

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Is there an association between atherosclerosis and chronic venous disease?

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2

LLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.

Diabetes Mellitus: A Cardiovascular Disease

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

AN EARLY WARNING SYSTEM FOR CARDIOVASCULAR DISEASE

New Guidelines in Dyslipidemia Management

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Fasting or non fasting?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

Prevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis Adequacy

CVD risk assessment using risk scores in primary and secondary prevention

The Role of Vitamin D in Heart Disease. Janet Long, MSN, ACNP, CLS, FAHA, FNLA Cardiovascular Institute Rhode Island Hospital and The Miriam Hospital

Cardiovascular Risk Reduction in Kidney Transplant Recipients

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

No relevant financial relationships

No relevant financial relationships

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

hypertension Head of prevention and control of CVD disease office Ministry of heath

Report and Opinion 2016;8(12)

Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Traitements associés chez l hypertendu: Statines, Aspirine

Peripheral Arterial Disease: Objectives. Disclosure. Definition: Peripheral Arterial Disease (PAD)

Screening and early recognition of CKD. John Ngigi (FISN) Kidney specialist

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret

Stefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

Introduction. Risk factors of PVD 5/8/2017

2013 Hypertension Measure Group Patient Visit Form

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

What s New in the Management of Peripheral Arterial Disease

HD Scanning: Velocities and Volume Flow

How is the dialysis patient different?

ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk

Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.

Cardiovascular Complications of Diabetes

Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis

Morbidity & Mortality from Chronic Kidney Disease

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France

The Diabetes Link to Heart Disease

Blood Pressure LIMBO How Low To Go?

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

A cohort study to find Incidence of Peripheral Arterial Disease in

THE CRITICAL ROLE OF NURSES. Helping patients take control of their LDL-C to lower the risk of MI and stroke.

The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.

Cho et al., 2009 Journal of Cardiology (2009), 54:

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

New Guidelines in Dyslipidemia Management

Estrogens vs Testosterone for cardiovascular health and longevity

Correlation of novel cardiac marker

Hemodialysis Fistula Maturation Consortium

Nutritional Cases with CKD HEMODIALYSIS

Joshua A. Beckman, MD. Brigham and Women s Hospital

End stage renal disease and Protein Energy wasting

Left ventricular hypertrophy: why does it happen?

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

PATIENTS AND METHODS:

Transcription:

Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology Unit- CHU Liège- Ulg- Belgium

Risk increase Atherothrombosis is a Systemic Disease: Increase for Myocardial Infarction and Stroke as a Function of ABI 2.5 Measurement 1 x 2.2 2.0 1.5 1.0 1.0 0.8 0.6 0.4 0.2 Ankle-brachial index (ABI) 1. Dormandy JA, Creager MA. Cerebrovasc Dis 1999; 9(suppl 1): 14.

Distribution of 83 HD patients according to CV risk and ABI % 100 90 80 70 60 50 40 30 20 10 0 < 0.9 0.9-1.0 1.0-1.1 1.1-1.2 1.2-1.3 >1.3 ABI no risk cv risk At least one cv complication: LVH; MI; stroke; Heart failure

AV fistula is the recommended vascular access in HD but Vascular access failure (stenosis and thrombosis) is frequent, especially due to atherosclerosis.

AVF problems Roy-Chaudhury, P. et al. J Am Soc Nephrol 2006;17:1112-1127 Copyright 2006 American Society of Nephrology

Aims of the study 1. Could ABI<0.9 be a risk indicator of vascular access failure? 2. Could repeating ABI measurements be useful in the follow up of patients, especially for the AV Fistula outcome?

METHODS Recording of Arteriovenous Fistula complications during 4y: thrombosis and stenosis requiring angioplasty -Ankle Brachial Index = [ Ankle SBP/Brachial SBP] (ABI) was measured after 1h of HD session on both ankles and on the non fistula arm. -The lowest ratio was retained. Technic: hand held doppler : Bidop ES-100V3 HADECO ABI measured at baseline, after 1 and 4 years later - Predialysis BP was averaged on the last 12 dialysis sessions. - Biological parameters averaged on the last 3 months (CRP, lipids, Ca-P, PTH, albumin, uric acid).

Patients characteristics (N=38) Age : 63.5y M/W : 22/16 Dialysis vintage : 6.2y Diabetes mellitus :10 Smokers : 21 Past history of CV events: 30 HTN: 33 Statins : 10

ABI modifications at 4 years interval ABI Baseline levels ABI levels 4 years later < 0.9 0.9 1.3 > 1.3 Unc. arteries * 0.9 1.3 n=20 4 10 1 5 < 0.9 n=14 11 1 0 2 1.3 n=4 N = 38 * uncompressible arteries 0 0 1 3

Contribution of a single ABI Last ABI ------> ABI <0.9 N=15 ABI >0.9 N=23 Age 71.6 ± 16 64.5 ± 17 M/W 9/6 13/10 Dialysis vintage (years) 7.7 ± 7 11.6 ± 11 VAF: thromb, stenosis 8 (53%) (4T, 4 S) 17 (74%) (13T, 4S) AVF survival time (m) 59 ± 46 Median: 60 80 ± 89 Median: 65 Smoking 14 (93%) 0.009 13 (56%) Calcifications (XR ay chest) 13 (87%) 0.04 14 (61%) 4y Mean Ca (mg/dl) 9.5 ± 0.5 0.02 8.5 ± 0.4 Predialytic SBP (at 4 years) Predialytic Pulse P (at 4 years) 153 ± 16 0.005 135 ± 20 82 ± 13 0.005 67 ± 15

Contribution of a single ABI Last ABI ------> ABI <0.9 N=15 ABI >0.9 N=23 Age 71.6 ± 16 64.5 ± 17 M/W 9/6 13/10 Dialysis vintage (years) 7.7 ± 7 11.6 ± 11 VAF: thromb, stenosis 8 (53%) (4T, 4 S) 17 (74%) (13T, 4S) AVF survival time (m) 59 ± 46 Median: 60 80 ± 89 Median: 65 Smoking 14 (93%) 0.009 13 (56%) Calcifications (XR ay chest) 13 (87%) 0.04 14 (61%) 4y Mean Ca (mg/dl) 9.5 ± 0.5 0.02 8.5 ± 0.4 Predialytic SBP (at 4 years) Predialytic Pulse P (at 4 years) 153 ± 16 0.005 135 ± 20 82 ± 13 0.005 67 ± 15

Contribution of repeated ABI measurements at different occasions. ABI evolution in 4 years ------> ABI <0.9 N=15 Unmeasurable ABI (uncompressible arteries)n=10 Age 71.6 ± 16 68.5 ± 12 M/W 9/6 7/3 Dialysis vintage (y) 7.7 ± 7 11.6 ± 11 VAF: thromb, stenosis 8 (53%)(4T,4S) 7 (70%) (7T) Smoking (current and former) 11 (73%) 0.05 4 (40%) Baseline P (mg/dl) 4.64 ± 0.9 5.45 ± 0.9 0.06 Baseline PixCa (mg²/dl²) Predialytic Pulse P (at 4 years) 39.6 ± 12 50 ± 9.6 0.04 82 ± 13 0.04 71 ± 17

Contribution of repeated ABI measurements at different occasions. ABI evolution in 4 years ------> ABI <0.9 N=15 Unmeasurable ABI (uncompressible arteries)n=10 Age 71.6 ± 16 68.5 ± 12 M/W 9/6 7/3 Dialysis vintage (y) 7.7 ± 7 11.6 ± 11 VAF: thromb, stenosis 8 (53%)(4T,4S) 7 (70%) (7T) Smoking (current and former) 11 (73%) 0.05 4 (40%) Baseline P (mg/dl) 4.64 ± 0.9 5.45 ± 0.9 0.06 Baseline PixCa (mg²/dl²) Predialytic Pulse P (at 4 years) 39.6 ± 12 50 ± 9.6 0.04 82 ± 13 0.04 71 ± 17

Discussion and Conclusions (1) In HD patients: - A single ABI measurement when <0.9 is associated with classical cardiovascular risk factors well-known in peripheral artery occlusive disease, but also a high risk of mortality (data not shown). - But, it does not predict an increase of vascular access failure frequency.

Discussion and Conclusions (2) In HD patients: - Modification of ABI during FU gives more information on the outcome of the AVF. - The uncompressible arteries at the lower limb was associated with a higher rate of AVF thrombosis and with more mineral metabolism abnormalities. - A low ABI value during FU was more often associated with smoking and very high PP. - We suggest that ABI should be regularly measured in HD population for estimation of CV risk but also of AV Fistula outcome!

Goodman, Am J Kidney Dis, 2004 Two types of risk factors

Traditional risk factors Older age Hypertension Male gender Elevated LDL and Decreased HDL cholesterol Diabetes mellitus Tobacco use Psychosocial stress Family history of CVD Non-traditional risk factors ECF overload Anemia Abnormal mineral metabolism Malnutrition Inflammation/Infection Thrombogenic factors Oxidative stress Proteinuria Uremic toxins

Ankle-Brachial Index m odifications in 1 and 3 years -Hemodialysis Patients- 10 8 6 Uncompressible arteries N obs. 4 2 0 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 ABI baseline ABI 1 year later ABI 3 years later